Zang YF papers

Network analysis of comorbid insomnia and depressive symptoms among psychiatric practitioners during the COVID-19 pandemic

Wed, 03/29/2023 - 18:00

J Clin Sleep Med. 2023 Mar 29. doi: 10.5664/jcsm.10586. Online ahead of print.


STUDY OBJECTIVES: Insomnia and depression are common mental health problems reported by mental health professionals during the COVID-19 pandemic. Network analysis is a fine-grained approach used to examine associations between psychiatric syndromes at a symptom level. This study was designed to elucidate central symptoms and bridge symptoms of a depression-insomnia network among psychiatric practitioners in China. The identification of particularly important symptoms via network analysis provides an empirical foundation for targeting specific symptoms when developing treatments for comorbid insomnia and depression within this population.

METHODS: A total of 10,516 psychiatric practitioners were included in this study. The insomnia severity index (ISI) and Patient Health Questionnaire-9 (PHQ-9) were used to estimate prevalence rates of insomnia and depressive symptoms, respectively. Analyses also generated a network model of insomnia and depression symptoms in the sample.

RESULTS: Prevalence rates of insomnia (ISI total score ≥ 8), depression (PHQ-9 total score ≥ 5) and comorbid insomnia and depression were 22.2% (95% CI: 21.4%%-22.9%), 28.5% (95% CI: 27.6%%-29.4%), and 16.0% (95% CI: 15.3%-16.7%), respectively. Network analysis revealed that "Distress caused by sleep difficulties" (ISI7) and "Sleep maintenance" (ISI2) had the highest strength centrality, followed by "Motor dysfunction" (PHQ8) and "Sad mood" (PHQ2). Furthermore, the nodes "Sleep dissatisfaction" (ISI4), "Fatigue" (PHQ4) and "Motor dysfunction" (PHQ8) had the highest bridge strengths in linking depression and insomnia communities.

CONCLUSIONS: Both central and bridge symptoms (i.e., Distress caused by sleep difficulties, Sleep maintenance, Motor dysfunction, Sad mood, Sleep dissatisfaction and Fatigue) should be prioritized when testing preventive measures and specific treatments to address comorbid insomnia and depression among psychiatric practitioners during the COVID-19 pandemic.

PMID:36988299 | DOI:10.5664/jcsm.10586